Physician profile
Jane Davidson
NPI 1881701787
$18,660.64
in general payments reported to CMS, 2019-2025
48 companies · $4,333 in 2025
The $4,333 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,201 · 2022: $3,875 · 2023: $2,948 · 2024: $4,303 · 2025: $4,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $375 · Education: $26.73 · Travel and Lodging: $4.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,178.26 |
| Consulting Fee | $375.00 |
| Education | $26.73 |
| Travel and Lodging | $4.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,567.58 | 2021-2025 | |
| Pfizer INC. | $1,097.45 | 2023-2025 | |
| Lilly USA, LLC | $866.59 | 2021-2025 | Kisunla, Reyvow, Emgality |
| Biohaven Pharmaceuticals, INC. | $825.64 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $785.62 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $751.19 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $661.62 | 2021-2025 | |
| Amgen INC. | $568.19 | 2021-2024 | Uplizna, Aimovig |
| Lundbeck LLC | $541.65 | 2021-2025 | Vyepti |
| Medtronic, INC. | $481.83 | 2021-2024 | Linq II |
| Ucb, INC. | $443.95 | 2023-2025 | Zilbrysq, Briviact, Nayzilam |
| Neurocrine Biosciences, INC. | $272.33 | 2022-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $271.57 | 2023-2025 | Xcopri |
| Upsher-Smith Laboratories LLC | $268.68 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $257.63 | 2024-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $252.96 | 2023-2024 | |
| Csl Behring | $241.45 | 2022-2025 | Hizentra, Kcentra |
| Neurelis, INC. | $215.88 | 2023-2025 | Valtoco |
| Axsome Therapeutics, INC. | $193.38 | 2025 | Symbravo |
| Averitas Pharma INC. | $189.12 | 2024 | Qutenza |
| Impel Pharmaceuticals LLC | $174.24 | 2024-2025 | Trudhesa |
| Alnylam Pharmaceuticals INC. | $149.74 | 2022-2025 | Amvuttra |
| Scilex Pharmaceuticals INC. | $147.30 | 2023-2025 | Ztlido |
| Astrazeneca Pharmaceuticals Lp | $142.86 | 2021 | |
| Novo Nordisk INC | $135.89 | 2025 | Wegovy |
| Incyte Corporation | $115.64 | 2024 | Opzelura |
| Allergan, INC. | $109.69 | 2021-2022 | |
| Mdd US Operations, LLC | $95.95 | 2022-2025 | Qelbree, Gocovri, Gocovri |
| Acadia Pharmaceuticals INC | $91.55 | 2021-2024 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $80.68 | 2021-2024 | Ultomiris |
| Tanabe Pharma America, INC. | $75.89 | 2022-2024 | |
| Argenx US, INC. | $75.24 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Ipsen Biopharmaceuticals, INC | $74.73 | 2024 | Dysport |
| Biogen, INC. | $49.48 | 2025 | Tysabri, Vumerity |
| Grifols USA, LLC | $45.47 | 2025 | Gamunex-C |
| Kyowa Kirin, INC. | $45.19 | 2024 | Nourianz |
| Amneal Pharmaceuticals LLC | $42.36 | 2023 | Rytary |
| Impel Pharmaceuticals INC. | $38.97 | 2023 | Trudhesa |
| Almatica Pharma LLC | $37.99 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.14 | 2024 | Hyqvia |
| Acorda Therapeutics, INC | $23.70 | 2022 | |
| Horizon Therapeutics Plc | $21.89 | 2021 | |
| Adamas Pharmaceuticals, INC. | $21.54 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.94 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.83 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.17 | 2024 | Nuedexta |
| Supernus Pharmaceuticals, INC. | $15.12 | 2021 | |
| Tonix Medicines, INC. | $14.14 | 2024 | Zembrace Symtouch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.